Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2016-02-22

FDA Approved: OPSUMIT — Supplemental Application (Actelion Pharmaceuticals US, Inc.)

View source ↗

Summary

FDA approved a supplemental application for OPSUMIT (macitentan) with updated labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • OPSUMIT (macitentan)

Snippet

SUPPL AP for OPSUMIT (MACITENTAN)